Research Use Only · Not for Human Consumption · For Laboratory & Research Purposes
Home·Products·KLOW
NewKLOW

KLOW

80 mg · 99.55% purity
$90Research Use Only

A quad-peptide combination of BPC-157, TB-500, GHK-Cu, and KPV targeting complementary angiogenic, cellular migration, extracellular matrix remodeling, and anti-inflammatory pathways in preclinical research.

Add to cart
Third-party testedSame-day shippingLyophilized · USA
Third-party tested
Independent HPLC identity & purity, 99%+, with a per-lot Certificate of Analysis.
Ships from the USA
Lyophilized and dispatched same-day from our U.S. facility.
Arrives safe or we replace it
Broken or damaged on arrival? Free replacement within 7 days. See our policy
Secure checkout
Encrypted checkout. Pay by crypto, Cash App, Zelle, or bank transfer.
Certificate of Analysis

Third-party tested, batch-by-batch

Every lot is independently verified for identity and purity by HPLC, and checked for appearance. View or download the full signed Certificate of Analysis for the current lot below.

LOT NLR-202607 · 80 mg
Identity (HPLC)Pass
Purity (HPLC)99.55%
AppearanceGood
Pairs Well

Frequently researched together

Compound Information

Technical specifications

KLOW is a lyophilized research blend combining four peptide compounds studied across complementary preclinical pathways. BPC-157, TB-500, and GHK-Cu are described in the GLOW entry above. The fourth component, KPV (Lysyl-Prolyl-Valine), is a tripeptide corresponding to the C-terminal sequence (residues 11–13) of alpha-melanocyte-stimulating hormone (α-MSH), an endogenous neuropeptide derived from proopiomelanocortin (POMC). KPV has been investigated in cell culture and rodent models for interactions with melanocortin receptors (specifically MC1R and MC3R) and downstream NF-κB signaling pathways implicated in inflammatory cytokine production. Studies have examined KPV in intestinal epithelial cell models and murine colitis models. This blend is formulated for in vitro and preclinical laboratory research only; controlled studies of this specific four-component combination in published literature have not been conducted.

Identity / Purity
99.55%
Format
Lyophilized powder
Size
80 mg
Lot
NLR-202607
Origin
Four synthetically manufactured research peptides: BPC-157 (gastric-derived sequence), TB-500 (Thymosin Beta-4 analogue), GHK-Cu (copper-binding tripeptide), and KPV (α-MSH C-terminal tripeptide)
Storage
−20°C, sealed
Key facts
  • BPC-157 and TB-500 are described fully in the GLOW research entry; KPV adds a fourth mechanistic pathway to this blend
  • KPV (Lys-Pro-Val) is the C-terminal tripeptide of α-MSH, a POMC-derived neuropeptide that signals through melanocortin receptors MC1R–MC5R
  • KPV has been shown to inhibit NF-κB nuclear translocation and reduce pro-inflammatory cytokine secretion (IL-8, IL-6) in human intestinal epithelial cell lines in vitro
  • Rodent studies have examined KPV administration in chemically induced colitis models (TNBS, DSS), with reported effects on mucosal inflammatory markers
  • Melanocortin receptor signaling has been studied as a regulatory axis in intestinal immune homeostasis in preclinical research
  • GHK-Cu chelates Cu²⁺ and modulates ECM gene expression in fibroblast models; combined mechanistic effects of all four components have not been characterized in controlled studies
  • Lyophilized blend; reconstitute with bacteriostatic water for in vitro use only
  • For research use only — not for human or veterinary administration
⚠️
For Research Use Only

All products sold by Next Level Research LLC are intended for laboratory and research use only. Not for human or animal consumption. Not a drug, food, or cosmetic. No therapeutic claims are made.